As patent lapses, generic weight loss shots may cost 60% less, Pg15

Key Highlights:

• The patent for semaglutide, a popular diabetes and weight loss drug, is set to expire on March 20.
• Approximately 50 generic brands of semaglutide are expected to enter the market, potentially reducing prices by at least 30%.
• Generic versions of semaglutide injectables are anticipated to cost between Rs 3,000 and Rs 4,000 per month.
• Novo Nordisk's Ozempic currently costs between Rs 8,800 and Rs 11,175 per month, while Wegovy costs between Rs 10,850 and Rs 16,400.
• Zydus Lifesciences plans to launch semaglutide pens with multiple dose options, improving convenience and adherence.
• The CDSCO has warned manufacturers against advertising these drugs under the guise of awareness campaigns.

Detailed Insights:

• The expiration of the semaglutide patent is expected to boost the weight loss drug market in India, with generic versions offering similar efficacy at lower costs.
• Semaglutide mimics the GLP-1 hormone, stimulating insulin production, lowering blood sugar, slowing digestion, and reducing appetite, initially approved for Type-2 diabetes by the FDA in 2017.
• While Eli Lilly’s tirzepatide (Mounjaro) holds a significant market share and its patent lasts until 2035, competition from generics may gradually impact its dominance.
• Market leaders like Novo Nordisk are unlikely to reduce prices despite competition, emphasizing the clinical evidence and safety of their products.
• The availability of lower-cost generics is expected to increase the number of users, particularly those previously deterred by high prices, potentially leading to a two-to-threefold surge.
• The CDSCO advisory aims to prevent misuse and unethical marketing practices, ensuring responsible promotion and prescription of these drugs.
• Potential adverse effects of semaglutide, such as nausea and gastrointestinal symptoms, necessitate medical supervision and responsible use, distinguishing between medical obesity management and cosmetic weight loss.

Key Concepts Involved:

• Semaglutide: A drug mimicking the GLP-1 hormone, used for treating Type-2 diabetes and obesity by regulating insulin and appetite.
• GLP-1 Hormone: A hormone released in the gut after eating, stimulating insulin production and reducing appetite.
• Generics: Medications equivalent to brand-name drugs in dosage, safety, strength, quality, and performance, but typically cheaper.
• CDSCO: The Central Drugs Standard Control Organisation, India's apex drug regulator responsible for drug approval and regulation.